Literature DB >> 23050328

Stability of omeprazole in SyrSpend SF Alka (reconstituted).

Paul A Whaley1, Mark A Voudrie, Bridget Sorenson.   

Abstract

Omeprazole is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. Omeprazole is marketed by AstraZeneca under a number of names, most notably Prilosec and Losec, as well as being available from a number of generic manufacturers. Omeprazole is available in both tablet and capsule form, with varying strengths of each. The need for other administration options for those patients who cannot take tablets or capsules has led compounding pharmacies to seek other alternatives. One possible alternative is the use of a suspending agent to create an oral solution or suspension. In the past, this has been accomplished using a sodium bicarbonate solution as the vehicle. However, sodium bicarbonate/omeprazole combination imparts a bitter and unpleasant taste. SyrSpend SF Alka (reconstituted) is a vehicle for making a suspension which has a pleasant taste, thus increasing palpability and compliance. The objective of this study was to determine the stability of omeprazole in SyrSpend SF Alka (for reconstitution). The studied sample was compounded into a 2-mg/mL suspension and stored in a low-actinic plastic prescription bottle at temperatures between 2 degrees C and 8 degrees C. Six samples were assayed at each time point out to 92 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced degradation studies. The shelf life of this product is at least 92 days, based on data collected when refrigerated and protected from light.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23050328

Source DB:  PubMed          Journal:  Int J Pharm Compd        ISSN: 1092-4221


  4 in total

1.  Limited Influence of Excipients in Extemporaneous Compounded Suspensions.

Authors:  Eli Dijkers; Valerie Nanhekhan; Astrid Thorissen; Diego Marro; Marta Uriel
Journal:  Hosp Pharm       Date:  2017-07-13

2.  A Critical Assessment of Extemporaneous Formulations for Proton Pump Inhibitors: The Importance of Proper Vehicle Selection.

Authors:  Ognjenka Rahić; Jasmina Hadžiabdić; Amina Tucak; Merima Sirbubalo; Lamija Hindija; Alisa Elezović; Edina Vranić
Journal:  J Pediatr Pharmacol Ther       Date:  2022-09-26

3.  Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.

Authors:  Hudson C Polonini; Sharlene L Silva; Thalyta R de Almeida; Marcos Antônio F Brandão; Anderson O Ferreira
Journal:  Eur J Hosp Pharm       Date:  2016-03-24

4.  Compatibility of proton pump inhibitors in a preservative-free suspending vehicle.

Authors:  Hudson C Polonini; Sharlene L Silva; Shirley Loures; Rachel Almy; Antoine Balland; Marcos Antônio F Brandão; Anderson O Ferreira
Journal:  Eur J Hosp Pharm       Date:  2016-11-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.